Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Gradishar

Showing results (161-170 of 195) with videos related to

Pageof 20
Sort By:
Biorxiv : the Preprint Server for Biology|April 24, 2023
Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasisEmma Schuster, Nurmaa Dashzeveg, Yuzhi Jia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Breast cancer risk reductionTherese B Bevers, Deborah K Armstrong, Banu Arun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 26, 2010
Breast cancer risk reductionTherese B Bevers, Deborah K Armstrong, Banu Arun, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 19, 2007
Invasive breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2005
Breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 26, 2010
Breast cancer: noninvasive and special situationsRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Pageof 20

Showing results (161-170 of 195) with videos related to

Sort By:
Pageof 20
Biorxiv : the Preprint Server for Biology|April 24, 2023
Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasisEmma Schuster, Nurmaa Dashzeveg, Yuzhi Jia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Breast cancer risk reductionTherese B Bevers, Deborah K Armstrong, Banu Arun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 26, 2010
Breast cancer risk reductionTherese B Bevers, Deborah K Armstrong, Banu Arun, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 19, 2007
Invasive breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2005
Breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 26, 2010
Breast cancer: noninvasive and special situationsRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Pageof 20